Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 2/20 | 0.51 |
| ▸ | F2 | P00734 | 11/20 | 0.48 |
| ▸ | F10 | P00742 | 5/20 | 0.48 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.41 |
| ▸ | TMPRSS11D | O60235 | 6/20 | 0.41 |
| ▸ | PLG | P00747 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6093799 | 0.92 | SCN4A (0.54) | SCN4AF2F10SCN3ATMPRSS11D | |
| SCHEMBL6094499 | 0.90 | SCN3A (0.54) | SCN4AF2F10SCN3ASCN5A | |
| SCHEMBL6094266 | 0.86 | TMPRSS11D (0.42) | F2F10TMPRSS11DPLG | |
| SCHEMBL7129383 | 0.86 | TMPRSS11D (0.42) | F2F10TMPRSS11DPLG | |
| SCHEMBL6094669 | 0.86 | SCN4A (0.48) | SCN4AF2F10SCN3ATMPRSS11D | |
| SCHEMBL6093332 | 0.83 | TMPRSS11D (0.43) | F2F10TMPRSS11DPLG | |
| Hydrochloric Acid SCHEMBL6093111 | 0.82 | SCN4A (0.57) | SCN4AF2F10SCN3ASCN5A | |
| SCHEMBL6093463 | 0.82 | TMPRSS11D (0.44) | F2F10TMPRSS11DPLG | |
| SCHEMBL6092937 | 0.82 | SCN4A (0.57) | SCN4AF2F10SCN3ASCN5A | |
| SCHEMBL6179403 | 0.81 | SCN4A (0.60) | SCN4AF2F10SCN3ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7112590-B2 | Thrombin inhibitors | LEK PHARMACEUTICALS D.D. (SI) | 2006-09-26 | — | — | US | claimed |
| EP-1287018-B1 | THROMBIN INHIBITORS | LEK TOVARNA FARMACEVTSKIH (SI) | 2005-01-19 | — | — | EP | claimed |
| US-20030191139-A1 | Thrombin inhibitors | UNIVERSITY OF LJUBLJANA (SI) | 2003-10-09 | — | — | US | claimed |
| US-7112590-B2 | Thrombin inhibitors | LEK PHARMACEUTICALS D.D. (SI) | 2006-09-26 | — | — | US | disclosed |
| EP-1287018-B1 | THROMBIN INHIBITORS | LEK TOVARNA FARMACEVTSKIH (SI) | 2005-01-19 | — | — | EP | disclosed |
| US-20030191139-A1 | Thrombin inhibitors | UNIVERSITY OF LJUBLJANA (SI) | 2003-10-09 | — | — | US | disclosed |
| EP-1287018-A2 | THROMBIN INHIBITORS | Lek Pharmaceutical and Chemical Co. D.D. (SI) | 2003-03-05 | — | — | EP | disclosed |
| WO-2001085760-A1 | THROMBIN INHIBITORS | LEK PHARMACEUTICAL & CHEMICAL CO. DD (SI) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191139-A1 | Thrombin inhibitors | TFPI, F2, SERPINC1 | SCN4A 3774/4885F2 2/4885F10 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.